GUOBANG PHARMA LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 17.45 CNY | -2.19% |
|
+4.74% | -0.63% |
| Apr. 15 | Guobang Pharma Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| Jan. 27 | Guobang Pharma Ltd. announces an Equity Buyback for CNY 200 million worth of its shares. | CI |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
Strengths
- Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
- The earnings growth currently anticipated by analysts for the coming years is particularly strong.
- Its low valuation, with P/E ratio at 9.89 and 8.06 for the ongoing fiscal year and 2025 respectively, makes the stock pretty attractive with regard to earnings multiples.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- The valuation of the company is particularly high given the cash flows generated by its activity.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Sector: Pharmaceuticals
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -0.63% | 1.34B | - | ||
| +30.38% | 684B | C+ | ||
| +26.51% | 568B | B | ||
| -4.36% | 361B | C+ | ||
| +19.30% | 329B | B- | ||
| +3.73% | 284B | C+ | ||
| +16.70% | 240B | B+ | ||
| +8.78% | 208B | B- | ||
| -7.93% | 200B | A+ | ||
| +7.68% | 166B | C+ |
Investor Rating
Trading Rating
-
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
-
Valuation
P/E ratio
EV / Sales
-
Price to Book
Price to Free Cash Flow
Yield
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
-
Business Predictability
Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- 605507 Stock
- Ratings Guobang Pharma Ltd.